S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

MRK Merck and Co Inc

108.5181

-1.23 (-1.12%)

19 Oct 2024 - Closed

Delayed by 15 minutes

A very strong day for Merck & Company Inc stock price on Friday

The Merck & Company Inc stock price gained 8.37% on the last trading day (Friday, 1st Oct 2021), ris... View Full Article on StockInvest.us

Merck (NYSE:MRK)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Merck Charts.

Merck (NYSE:MRK)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Merck Charts.

Merck and Co Inc News

Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
Friday 18 October 2024 (2 days ago) • Business Wire

Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
Wednesday 16 October 2024 (3 days ago) • Business Wire

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
Monday 14 October 2024 (5 days ago) • Business Wire

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Wednesday 9 October 2024 (1 week ago) • Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Tuesday 8 October 2024 (2 weeks ago) • Business Wire

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Thursday 3 October 2024 (2 weeks ago) • InvestorsHub NewsWire

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More
Thursday 3 October 2024 (2 weeks ago) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 2 October 2024 (3 weeks ago) • Edgar (US Regulatory)

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Tuesday 1 October 2024 (3 weeks ago) • Business Wire

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Tuesday 1 October 2024 (3 weeks ago) • Business Wire

More Merck and Co Inc News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions